Norgine B.V has said that the company has appointed Christopher Bath as the company’s new Chief Operating Officer (COO) effective from July 1st, 2020. The newly appointed company’s COO has served the company as Chief Financial Officer since 2014 and he will directly report to the Chief Executive Officer and Chairman of the company. Peter Stein.
The company’s former Chief Operating Officer, Peter Martin, will continue to serve the company in a non-Executive capacity.
The company has direct presence in 12 different European Countries, including New Zealand and Australia. The company has created a fully integrated pharmaceutical business with manufacturing facilities in Dreux, Wales, Hengoed and France.
Chief Executive Officer of company, Peter Stein said on the occasion, “In his previous role as Norgine’s Chief Financial Officer and a member of the Executive Team, Chris has demonstrated strong leadership, driving robust organic growth as well as acquisitions, including the transformational acquisition of Merus in 2017 and most recently the acquisition of Azanta in 2020. Under Peter Martin’s long-term leadership,”
“Norgine saw a sustained period of year on year growth and today we are proud to be able to help 22 million patients every year. I am confident that Chris will further develop the company enabling us to help more patients worldwide in the years to come. I look forward to continuing to work with Peter Martin in his new non-Executive role,” Peter Stein concluded.
The company’s newly appointed Chief Operating Officer, Christopher Bath said, “Our commitment to transforming people’s lives drives everything we do at Norgine and I am pleased and honoured to be appointed as the company’s Chief Operating Officer. I am looking forward to building on our exceptional foundation as a leading European pharmaceutical company so we can bring innovative healthcare products to patients in Europe and around the world.”